Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of Lebrikizumab in Healthy Chinese Participants
NCT06243198Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2024
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lebrikizumab in atopic dermatitis (AD) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) up to 120 days. Started Mar 2024; status: completed.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06243198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06243198.